



Supplementary Figure 1. Comparison of COVA1-16 and putative germline sequences. Alignment of COVA1-16 Fab amino-acid sequence with (A) germline IGHV1-46 sequence, and (B) germline IGKV1-33 sequence. The regions that correspond to CDR H1, H2, H3, L1, L2, and L3 are indicated. Residues that differ from germline are highlighted in red. COVA1-16 Fab residues that interact with the RBD are highlighted in yellow. Residue positions in the CDRs are labeled according to the Kabat numbering scheme. (C) Amino acid and nucleotide sequences of the V-D-J junction of COVA1-16, with putative

- 9 gene segments (blue) and N-regions (red), are indicate. The germline sequences of
- 10 IGHD3-22 and IGHJ1 are also shown. The only somatically mutated nucleotide in the D
- 11 region is underlined.



Supplementary Figure 2. Competition assay between different IgGs and ACE2. Competition between COVA1-16 IgG, CR3022 IgG, and Fc-tagged ACE2 was measured by biolayer interferometry (BLI). Y-axis represents the response. The biosensor was first loaded with SARS-CoV-2 RBD, followed by two binding events: 1) CR3022 IgG or COVA1-16 IgG, and 2) ACE2, CR3022 IgG, or COVA1-16 IgG. A period of 300 s was used for each binding event. A further increase in signal during the second binding event (starting at 300 s time point) indicates lack of competition with the first ligand.










23 Supplementary Figure 3. Negative-stain EM analysis of COVA1-16 binding to SARS-24 CoV-2 S trimer. (A) An atomic model from the crystal structure of SARS-CoV-2 RBD 25 bound to COVA1-16 Fab was fit into the negative-stain EM reconstruction of the SARS-26 CoV-2 spike bound to COVA1-16 Fab. The COVA1-16 Fab approaches the apex of the S 27 trimer in a perpendicular orientation. A secondary structure backbone representation of 28 the prefusion spike model (PDB: 6Z97, green) [1] was also fit into the EM density with 29 RBD residues (334-528) removed from one of the protomers here for clarity. The COVA1-30 16 heavy and light chains are in magenta and pink, respectively, and COVA1-16-bound 31 RBD in yellow. (B) Conformation of RBD in an up conformation from an unliganded SARS-32 CoV-2 S trimer (PDB: 6Z97, green) [1] is compared to that of the RBD (yellow) bound by 33 COVA1-16 Fab. The arrow indicates that the RBD further rotates and opens up when 34 bound to COVA1-16, thereby moving further away from the trimer threefold axis. (C) An 35 atomic model of the spike RBD bound to COVA1-16 Fab is fit into a negative-stain EM 36 reconstruction, where COVA1-16 Fab approaches the SARS-CoV-2 S trimer from the 37 side. COVA1-16 is modelled as an IgG to illustrate the feasibility of bivalent binding to 38 adjacent spike proteins on the virus surface. The Fab heavy and light chains are shown in 39 magenta and pink. A schematic representation of the Fc domain of the IgG is shown in


40 magenta. The RBD model and spike density for each trimer is shown in yellow and cyan.



42 Supplementary Figure 4. Sensorgrams for binding of COVA1-16 to SARS-CoV-2 43 RBD and SARS-CoV RBD. (A-B) Binding kinetics of COVA1-16 Fab and IgG to (A) 44 SARS-CoV-2 RBD and (B) SARS-CoV RBD were measured by biolayer interferometry 45 (BLI) with RBD on the biosensor and antibody in solution. Y-axis represents the response. 46 An anti-HIV His-tagged Fab (4E1) was used as a negative control. Dissociation constants 47 (K_D) for IgG and Fab were obtained using a 1:2 bivalent model and 1:1 binding model, 48 respectively, which are represented by the black lines. Representative results of two 49 replicates for each experiment are shown. (C) The relationship between SARS-CoV-2 50 RBD loading concentration on the biosensor and the dissociation constant of COVA1-16 51 IgG is shown.








- 62
- 63 Supplementary Figure 6. CDR H3 of COVA1-16 Fab is disordered in its unliganded
- 64 **apo form. (A)** In the crystal structure of the RBD-bound form of COVA1-16 Fab, the
- 65 CDR H3 loop is completely ordered (red). (B) In the crystal structure of the apo form of
- 66 COVA1-16, the distal end of the CDR H3 loop is intrinsically disordered or flexible (red).

	319
SARS-CoV-2	RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA-SFSTFKCYGVSPTKLNDLCF
Pangolin-CoV	RVQPTESIVRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSV <mark>LYNST</mark> -S <mark>F</mark> ST FKCYGVSPT KLNDLCF
RaTG13	RVQPTDSIVRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSV <mark>LYNST</mark> -S <mark>F</mark> ST <mark>FKCYGVSPT</mark> KLNDLCF
WIV1	RVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSV <mark>LYNST</mark> -S <mark>F</mark> ST <mark>FKCYGVSAT</mark> KLNDLCF
WIV16	RVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSV <mark>LYNST</mark> -S <mark>F</mark> ST <mark>FKCYGVSAT</mark> KLNDLCF
SARS-CoV	RVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSV <mark>LYNST</mark> -F <mark>F</mark> ST <mark>FKCYGVSAT</mark> KLNDLCF
BM48-31	RVTPTTEVVRFPNITOLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFOCYGVSPTKLNDLCF
GX2013	RVSPTQEVVRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNST-SFSTFKCYGVSPSKLIDLCF
HKU3-1	RVSPTOEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNST-SFSTFKCYGVSPSKLIDLCF
ZC45	RVQPTQSVVRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNST-SFSTFKCYGVSPSKLIDLCF
ZXC21	RVQPTQSIVRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNST-SFSTFKCYGVSPSKLIDLCF
Longquan-140	RVSPTOEVIRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCIADTTVFTNST-SFSTFKCYGVSPSLIDLCF
HuB2013	RVTPTQEVVRFPNITNRCPFDRVFNASRFPSVYAWERTKISDCVADTTVLTNST-SFSTFKCYGVSPSLIDLCF
Rp3	RVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNST-SFSTFKCYGVSPSKLIDLCF
Rs672	RVSPTHEVIRFPNITNRCPFDKVFNASRFPNVYAWERTKISDCVADYTV <mark>LYNST</mark> -S <mark>F</mark> ST <mark>FKCYGVSPS</mark> KLIDLCF
Rf1	RVSPVTEVVRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTV <mark>FYNST</mark> -S <mark>F</mark> ST <mark>FNCYGVSPS</mark> KLIDLCF
SX2013	RVSPVTEVVRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTV <mark>FYNST</mark> -S <mark>F</mark> ST <mark>FNCYGVSPS</mark> KLIDLCF
	393
SARS-CoV-2	TNVYADSFVIRGDEV <mark>RQIAPGQTGK</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNSNNLDSKV <mark>G</mark> GN <mark>Y</mark> NYL <mark>Y</mark> R <mark>LF</mark> RKSNLKPFERD
Pangolin-CoV	TNVYADSFVVRGDEV <mark>RQIAPGQTGR</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNSNNLDSKV <mark>G</mark> GN <mark>Y</mark> NYL <mark>YRLF</mark> RKSNLKPFERD
RaTG13	TNVYADSFVITGDEVROIAPGOTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERD
WIV1	SNVYADSFVVKGDDV <mark>ROIAPGOTGV</mark> IADYNYKLPDDFTGCVLAWNTRNIDATO <mark>T</mark> GN <mark>Y</mark> NYKY <mark>RSL</mark> RHGKLRPFERD
WIV16	SNVYADSFVVKGDDVR0IAPG0TGVIADYNYKLPDDFTGCVLAWNTRNIDAT0TGNVNYKVRSLRHGKLRPFERD
SARS-CoV	SNVYADSFVVKGDDVROIAPGOTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERD
BM48-31	
GX2013	SVIADTFVIKBUNGLAPGETGVIADINTKLPDDFTGCVIAWNTAKQDTGNYYYRSHRKTKLKPFERD TSVYADTFLIRSSEVRQVAPGETGVIADINYKLPDDFTGCVIAWNTAKQDTGNYYRSHRKTKLKPFERD TSVYADTFLIRFSEVRQVAPGQTGVIADINYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRKTKLKPFERD TSVYADTFLIRFSEVRQVAPGQTGVIADINYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRKTKLKPFERD TSVYADTFLIRSSEVRQVAPGGTGVIADINYKLPDDFTGCVIAWNTAKQDTGNYYYRSHRKTKLKPFERD TSVYADTFLIRSSEVRQVAPGETGVIADINYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERD TSVYADTFLIRSSEVRQVAPGETGVIADINYKLPDDFTGCVIAWNTAKQDTGNYYRSHRKTKLKPFERD TSVYADTFLIRSSEVRQVAPGETGVIADINYKLPDDFTGCVIAWNTAKQDTG
HKU3-1	ISVTADIFLIKSSEVKVAPGE IGVIAUTNTKLPDDFIGVIANNIAKHDIGNTTKSHKIKLKPFERD
ZC45	TSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFTRSTKLKPFERD
ZXC21	TSVYADTFLIRFSEV <mark>RQ</mark> VA <mark>PGQTGV</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNTAKQDTG- <mark>-</mark> HYF <mark>Y</mark> R <mark>SH</mark> RSTKLKPFERD
Longquan-140	TSVYADTFLIRSSEV <mark>RQ</mark> VA <mark>PGETGV</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNTAKQDIG- <mark>-</mark> <mark>-</mark> NYY <mark>Y</mark> R <mark>SH</mark> RKTKLKPFERD
HuB2013	TSVYADTFLIRSSEV <mark>RQ</mark> VA <mark>PGETGV</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNTAKQDTG- <mark>-</mark> YYY <mark>Y</mark> R <mark>SH</mark> RKTKLKPFERD
Rp3	TSVYADTFLIRSSEV <mark>RQ</mark> VA <mark>PGETGV</mark> IADYNYKLP <mark>DDF</mark> TGCVIAWNTAKQDQG- <mark>-</mark> <mark>-</mark> QYY <mark>YRSH</mark> RKTKLKPFERD
Rs672	
Rf1	TSVYADTFLIRFSEVROVAPGOTGVIADYNYKLPDDFTGCVIAWNTAKODVGSYFYRSHRSSKLKPFERD
SX2013	TSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERD TSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERD
	468
SARS-CoV-2	ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF
Pangolin-CoV	ISTEIYQAGSTPCNGVEG <mark>FNCY</mark> FPL <mark>Q</mark> SY <mark>GFHPTNG</mark> VG <mark>Y</mark> QPYRVVVLSFELLNAPATVCGPKQSTNLVKNKCVNF
RaTG13	ISTEIYOAGSKPCNGOTGLNCYYPLYRYGFYPTDGVGHOPYRVVVLSFELLNAPATVCGPKKSTNLVKNKCVNF
WIV1	ISNVPFSPDGKPCT-PPAFNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF
WIV16	ISNVPFSPDGKPCT-PPAFNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF
	ISNVPFSPDGRFCT-PPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF
SARS-CoV	
BM48-31	LSNVLFNPSGGTCS-AEGLNCYKPL <mark>A</mark> SYG <mark>FTQSSGIGFQ</mark> PYRVVVLSFELLNAPATVCGPKQSTELVKNKCVNF
GX2013	LSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNF
HKU3-1	LS <mark>-</mark> SDD <mark>GNGV</mark> YTL <mark>S</mark> TY <mark>DFNPNVP</mark> VA <mark>Y</mark> QATRVVVLSFELLNAPATVCGPKLSTĚLVKNQCVNF
ZC45	LS <mark>-</mark> SDE <mark>-N</mark> GVRTL <mark>S</mark> TY <mark>DFNPNVP</mark> LE <mark>Y</mark> QATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNF
ZXC21	LSSDE <mark>-NGV</mark> RTL <mark>S</mark> TYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNF
Longquan-140	LS <mark>-</mark> SDD <mark>GNGV</mark> YTL <mark>S</mark> TYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNF
HuB2013	LSSDDGNGVYTLSTYDENPNVPVAYOATRVVVLSEELLNAPATVCGPKLSTELVKNOCVNE
Rp3	LSSDE-NGVRTLSTYDFYPSVPVAY0ATRVVVLSFELLNAPATVCGPKLSTOLVKNOCVNF
Rs672	LTSDE-NGVRTLSTYDFYPNVPIEYQATRVVVLSFELLNAPATVCGPKLSTGLVKNQCVNF
Rf1	LSSEE-NGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTSLVKNQCVNF
SX2013	LSSEE NGVRTLSTTDTNGVPLETQATRVVVSFELLNAPATVCGPKLSTSLVKNQCVNF
372013	


Supplementary Figure 7. Sequence alignment of the RBD from SARS-related coronaviruses. Amino-acid sequences of RBDs from SARS-CoV-2, SARS-CoV, and other SARS-related coronavirus (SARSr-CoV) strains are aligned. COVA1-16 epitope residues are highlighted in cyan. ACE2-binding residues are highlighted in purple. Conserved residues are indicated by small black dots on the top of the alignment.




73

Supplementary Figure 8. Sequence conservation of S309 epitope. Sequence conservation of the RBD is highlighted on the structure for S309 epitope [2]. This view corresponds to the opposite side (rotated 180 degrees along the vertical axis) from that shown in Figure 4A-B.

COVA1-16 epitope




- 80 Supplementary Figure 9. COVA1-16 epitope in electrostatic surface representation.
- 81 The epitope of COVA1-16 is outlined and shows its largely polar nature.




83 Supplementary Figure 10. Location of residues of interest in the COVA1-16 epitope 84 when all three RBDs are in the "down" conformation. (A) The RBD of one of the three 85 protomers is shown as a gray cartoon with the side chains of five residues of interest 86 shown in yellow stick representation. RBD residues K378, R408, Q414, and D427 are 87 within the COVA1-16 epitope, whereas K386 is not a COVA1-16 epitope residue. The 88 other two protomers (protomers 2 and 3) are shown in a surface electrostatic 89 representation. (B-E) Zoomed-in views for the regions surrounding residues (B) R408 and 90 Q414, (C) D427, (D) K378, and (E) K386. A hydrogen bond in (B) is represented by a 91 dashed line. Due to charge difference or similarity between the side chain and the proximal 92 region of the neighboring protomer, either repulsive (same charge) or attractive (opposite 93 charge) environments are found and visualized here. PDB 6VXX is used to represent the 94 spike protein [3]. Of note, the shape complementarity values (Sc) [4] of the COVA1-16 95 epitope/RBD interface, COVA1-16 epitope/S2 interface, and COVA1-16 epitope/COVA1-96 16 interface are 0.53, 0.75, and 0.74, respectively, indicating good complementary and 97 tight fit of the COVA1-16 epitope surface with the rest of the trimer in the RBD down

- 98 conformation. Sc values can range from 0 to 1, with a larger Sc value represents higher
- 99 shape complementarity.



102 Supplementary Figure 11. The N-glycan on the N-terminal domain (NTD) also 103 shields part of the RBD. The antibody-bound RBD, which is displayed and colored as in 104 Figure 5, is shown in the up conformation on the S protein (PDB 6VSB) [5]. N-glycans on 105 N165 (NTD), N234, N331, and N343 (RBD) are modelled according to the main glycoform 106 observed at these sites in [6], and shown in stick representation. Antibody Fabs from 107 published crystal and cryo-EM structures are represented as globular outlines in different 108 colors as outlined in Figure 5. B38, CB6, C105, CC12.1, CC12.3, COVA2-04, COVA2-39, 109 BD23, P2B-2F6 all bind at or around the receptor binding site. S309 binds to the elongated 110 accessible face of the RBD in both up and down conformations, and CR3022 binds to the 111 opposite face that is exposed in the RBD up conformation, but buried in the RBD down 112 conformation.



114

115 Supplementary Figure 12. Sensorgrams for binding of COVA1-16 lgG to SARS-CoV-116 2 RBD WT or mutants. Binding kinetics of COVA1-16 IgG to SARS-CoV-2 RBD WT, 117 A372T, and P384A were measured by biolayer interferometry (BLI) with RBD on the 118 biosensor and antibody in solution. Y-axis represents the response. Dissociation 119 constants (K_D) for Fabs were obtained using a 1:1 binding model, which are represented 120 by the red lines. Representative results of two replicates for each experiment are shown. 121 A372T and P384A are the only two mutations that differ between the SARS-CoV-2 and 122 SARS-CoV sequences in COVA1-16 epitope. The affinity of COVA1-16 IgG to the A372T 123 mutant did not show any detectable difference from WT. Although the affinity (K_D) of 124 COVA1-16 IgG to the P384A mutant decreases, the binding is still 100 times tighter than 125 that measured between COVA1-16 IgG and SARS-CoV RBD (Figure S4B). As a result, 126 the binding affinity of COVA1-16 to the RBD may be influenced by residues outside of the 127 epitope as well as the dynamics of the RBD fluctuations between up and down 128 conformations.

Supplementary Table 1. X-ray data collection and refinement statistics

Data collection		
	COVA1-16 Fab + SARS-CoV-2 RBD	COVA1-16 Fab
Beamline	SSRL 12-1	SSRL 12-1
Wavelength (Å)	0.97946	0.97946
Space group	<i>P</i> 1 2 ₁ 1	P 41 3 2
Unit cell parameters		
a, b, c (Å)	57.4, 124.9, 57.6	156.3, 156.3, 156.3
α, β, γ (°)	90, 96.1, 90	90, 90, 90
Resolution (Å) ^a	50.0-2.89 (2.95-2.89)	50.0-2.53 (2.58-2.53)
Unique reflections ^a	17,656 (845)	22,357 (1,084)
Redundancy ^a	3.7 (3.2)	37.0 (14.1)
Completeness (%) ^a	97.9 (93.9)	100.0 (100.0)
<l oi=""> a</l>	7.4 (1.2)	21.5 (1.3)
<i>R</i> _{sym} ^b (%) ^a	15.3 (69.1)	23.6 (>100)
R _{pim} ^b (%) ^a	9.0 (42.9)	3.8 (54.3)
CC _{1/2} ^c (%) ^a	96.3 (66.8)	99.6 (52.1)
Refinement statistics		
Resolution (Å)	42.8-2.89	34.1-2.53
Reflections (work)	17,632	21,872
Reflections (test)	948	1,069
R _{cryst} ^d / R _{free} ^e (%)	23.7/29.4	21.2/24.4
No. of atoms	4,873	3,284
Macromolecules	4,845	3,223
Glycans	28	-
Average B-values (Å ²)	49	43
Macromolecules	49	43
Fab	45	43
RBD	56	-
Glycans	89	-
Wilson <i>B</i> -value (Å ²)	43	40
RMSD from ideal geometry		
Bond length (Å)	0.004	0.007
Bond angle (°)	0.74	1.02
Ramachandran statistics (%) ^f		
Favored	95.9	96.7
Outliers	0.16	0.0
PDB code	pending	pending

^a Numbers in parentheses refer to the highest resolution shell.

131 132 133 134 135 136 137 138 ^b $R_{sym} = \Sigma_{hkl} \Sigma_i |I_{hkl,i} - \langle I_{hkl} \rangle | / \Sigma_{hkl} \Sigma_i |I_{hkl,i}$ and $R_{pim} = \Sigma_{hkl} (1/(n-1))^{1/2} \Sigma_i |I_{hkl,i} - \langle I_{hkl} \rangle | / \Sigma_{hkl} \Sigma_i |I_{hkl,i}$, where $I_{hkl,i}$ is the scaled intensity of the ith measurement of reflection h, k, l, $< I_{hkl} >$ is the average intensity for that reflection, and n is the redundancy.

 c CC_{1/2} = Pearson correlation coefficient between two random half datasets.

^d R_{cryst} = Σ_{hkl} | $F_o - F_c$ | $/ \Sigma_{hkl}$ | F_o | x 100, where F_o and F_c are the observed and calculated structure factors, respectively.

^e R_{free} was calculated as for R_{crvst}, but on a test set comprising 5% of the data excluded from refinement.

^f From MolProbity [7].

140Supplementary Table 2. Hydrogen bonds identified in the antibody-RBD interface141using the PISA program

COVA1-16 Fab	Distance [Å]	SARS-CoV-2 RBD
H:ARG100b[NH2]	3.3	A:TYR369[O]
H:ARG100b[NE]	3.9	A:SER371[O]
H:ARG100b[N]	3.8	A:PHE377[O]
H:TYR100[N]	2.6	A:CYS379[O]
H:GLN101[NE2]	3.1	A:GLN414[OE1]
H:ARG97[NH1]	2.5	A:ASP427[O]
H:TYR32[OH]	3.1	A:ASP427[OD1]
H:THR28[N]	3.2	A:ASP427[OD2]
H:ARG97[NH1]	3.0	A:PHE429[O]
H:TYR100[O]	2.9	A:CYS379[N]
H:SER100c[O]	3.3	A:THR385[OG1]
H:GLN101[OE1]	3.8	A:GLN414[NE2]
L:ASN53[OD1]	3.2	A:ARG408[NH2]
L:LEU54[O]	3.7	A:ARG408[NE]

144 SUPPLEMENTARY REFERENCES

- Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe. 2020. Epub 2020/06/26. doi: 10.1016/j.chom.2020.06.010. PubMed PMID: 32585135; PubMed Central PMCID: PMCPMC7303615.
- Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Crossneutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
 Nature. 2020. Epub 2020/05/19. doi: 10.1038/s41586-020-2349-y. PubMed
 PMID: 32422645.
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure,
 function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell.
 2020;181:281-92.e6. Epub 2020/03/11. doi: 10.1016/j.cell.2020.02.058. PubMed
 PMID: 32155444.
- Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces.
 J Mol Biol. 1993;234(4):946-50. Epub 1993/12/20. doi: 10.1006/jmbi.1993.1648.
 PubMed PMID: 8263940.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo EM structure of the 2019-nCoV spike in the prefusion conformation. Science.
 2020;367:1260-3. Epub 2020/02/23. doi: 10.1126/science.abb2507. PubMed
 PMID: 32075877.
- Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330-3. Epub 2020/05/06. doi: 10.1126/science.abb9983. PubMed PMID: 32366695; PubMed Central PMCID: PMCPMC7199903.
- Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et
 al. MolProbity: all-atom structure validation for macromolecular crystallography.
 Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12-21. doi:
 10.1107/S0907444909042073. PubMed PMID: 20057044; PubMed Central
 PMCID: PMCPMC2803126.
- 173